Get the Daily Brief
Latest Biotech News
AstraZeneca’s blood pressure breakthrough validates $1.3B CinCor acquisition
AstraZeneca’s experimental drug baxdrostat demonstrated statistically significant reductions in systolic blood pressure among patients with uncontrolled or resistant hypertension in a pivotal...
Takeda’s orexin agonist posts twin phase 3 wins – Narcolepsy filing imminent
Takeda’s novel orexin receptor 2 selective agonist, oveporexton, achieved all primary and secondary endpoints in two pivotal Phase 3 narcolepsy studies. The oral drug demonstrated clinically...
FDA rejects Ultragenyx gene therapy – Manufacturing flaws halt Sanfilippo treatment
The FDA issued a complete response letter declining approval of Ultragenyx’s gene therapy UX111 for Sanfilippo syndrome Type A, citing manufacturing process issues. The regulatory setback arises...
Private equity fuels PCI Pharma’s global drug production expansion at $10B valuation
PCI Pharma Services secured new investments from Bain Capital, Kolberg, and Mubadala, valuing the contract development and manufacturing organization (CDMO) at approximately $10 billion. The funds...
Viome and Scripps partner on at-home RNA colon cancer screening – 1000-patient trial set
Personalized medicine firm Viome and Scripps Research launched a collaboration to develop and clinically validate a non-invasive RNA-based test for early detection of precancerous colon polyps....
Integrated Biosciences unveils optogenetic platform – New path for targeted drug discovery
Biotech startup Integrated Biosciences introduced an innovative optogenetic screening platform integrating chemistry and AI to discover small molecule modulators with precision. Demonstrated...
Genomic AI breakthrough: DeepMind’s AlphaGenome decodes noncoding DNA impact
DeepMind’s AlphaGenome AI system can analyze up to one million DNA base pairs to predict functional effects of noncoding genetic variations linked to diseases like cancer and rare disorders. This...
Cancer immunotherapy response shaped by tumor genetics – Mouse model study reveals
Researchers using genetically diverse Collaborative Cross mice demonstrated that inherited genetic variability significantly influences tumor response to immune checkpoint inhibitors. This...
Alpha Tau Medical’s alpha radiation therapy induces systemic anti-cancer immune response
Alpha Tau Medical’s Alpha DaRT Phase 3 trials demonstrate 100% tumor response in treating solid tumors by delivering localized alpha radiation directly into lesions. Notably, the treatment elicits...
European biotech investment hurdle: Integration and market focus needed for growth
Industry leaders at BIO 2025 highlighted Europe's rich scientific innovation contrast with challenges in business integration, clinical trials, and fundraising compared to the U.S. Fragmented hubs...
Viome Partners With Scripps on At-Home RNA Test for Colon Cancer Screening
Viome Life Sciences and Scripps Research have launched a collaboration to develop an at-home RNA screening test aimed at early detection of precancerous colon polyps. The initiative involves a...
Takeda’s Orexin Agonist Shows Positive Phase 3 Results in Narcolepsy
Takeda’s orexin receptor 2-selective agonist, oveporexton (formerly TAK-861), achieved all primary and secondary endpoints across two Phase 3 trials targeting narcolepsy. The oral drug...
FDA Rejects Ultragenyx’s Gene Therapy Over Manufacturing Issues
Ultragenyx Pharmaceuticals received a complete response letter from the U.S. Food and Drug Administration concerning its AAV-based gene therapy UX111 for Sanfilippo syndrome due to manufacturing...
Evercore Initiates Guardant Health Coverage With Bullish Outlook
Investment bank Evercore ISI initiated coverage of Guardant Health, assigning an Outperform rating with a $60 price target. Evercore projects over 20% annual top-line growth through 2027, driven...
WHO Adds Gilead’s Twice-Yearly HIV PrEP Injection to Guidelines
Following FDA approval, the World Health Organization expanded its global HIV prevention guidelines to include Gilead Sciences’ twice-yearly cabotegravir injection for pre-exposure prophylaxis....
Integrated Biosciences Unveils Optogenetic Drug Screening Platform
Integrated Biosciences introduced a novel optogenetic screening platform enabling precise modulation of biological pathways with light. Applying this technology, the company screened over 370,000...
AstraZeneca’s Blood Pressure Drug Baxdrostat Achieves Phase 3 Success
AstraZeneca announced positive Phase 3 results for baxdrostat, an aldosterone synthase inhibitor for treatment-resistant hypertension. The drug met primary and secondary endpoints in a late-stage...
Alpha Tau Medical’s Alpha DaRT Shows Promising Cancer Immunotherapy Results
Alpha Tau Medical reported encouraging Phase 3 clinical trial results for Alpha DaRT, a localized alpha radiation therapy for solid tumors. The treatment elicits both local tumor control and...
Genetic Diversity Influences Tumor Response to Immunotherapy
A study using genetically diverse Collaborative Cross mouse models revealed that inherited genetic variability significantly affects tumor response to immune checkpoint inhibitors. Published in...
Multi-Protein Misfolding Identified as Contributor to Alzheimer’s Beyond Amyloids
Johns Hopkins researchers used limited proteolysis mass spectrometry to identify over 200 misfolded proteins associated with cognitive decline in aging rat brains, suggesting that neurological...